Mr. Erez Tetro reports

VVT MED ANNOUNCES APPLICATION FOR MANAGEMENT CEASE TRADE ORDER

VVT Med Inc. has made an application to the British Columbia Securities Commission to approve a temporary management cease trade order (the MCTO) under National Policy 12-203 -- Cease Trade Orders for Continuous Disclosure Defaults, which, if granted, will prohibit trading in securities of the company by the chief executive officer and chief financial officer of the company until such time as the required filings (as defined below) and all continuous disclosure requirements have been filed by the company, and the MCTO has been lifted. During the period in which the MCTO is effective, the general public, who are not insiders of the company, will continue to be able to trade in the company's listed securities. The MCTO application has been made, but there is no guarantee or assurance that the MCTO will be granted.

The company expects that it will be unable to file its audited annual financial statements for the year ended Dec. 31, 2025, together with the related management's discussion and analysis, and chief executive officer and chief financial officer certifications, on or before the April 30, 2026, filing deadline.

The anticipated delay in filing the required filings is due to external circumstances beyond the company's control. While the company has worked diligently to meet its continuous disclosure obligations, the continuing armed conflict in the Middle East has caused significant disruptions to the operational and administrative processes required to finalize the company's annual reporting and audit. These regional challenges, which include restricted access to essential resources and personnel availability at the company and various service providers in Israel, have necessitated an extension of the reporting timeline.

The company remains committed to completing the filing as soon as practicable. The company wishes to clarify that this delay is purely administrative in nature, does not arise from any disagreement with its auditor, and there are no material uncertainties regarding the company's financial position. The company anticipates that it will be in a position to remedy the default by filing the required filings on or before June 30, 2026. The MCTO will be in effect until the required filings are completed.

In accordance with NP 12-203, the company will provide biweekly status updates by way of news releases for so long as the required filings remain outstanding. The company does not anticipate any additional specified defaults under NP 12-203.

About VVT Med Inc.

VVT is the only Food and Drug Administration-cleared, stand-alone company offering non-thermal, non-tumescent (NT-NT) varicose vein treatment technology. VVT's catheter-based technologies, ScleroSafe and V-Block, enable safe, office-based procedures with no anesthesia or downtime. Addressing the widest range of vein diameters, VVT's solutions empower physicians to treat both the medical and aesthetic aspects of vein disease via a cost-efficient, simultaneous sclerosant injection and blood aspiration process. The company's patented technology portfolio includes 55 patents from 14 patent families across 20 countries, providing broad global intellectual property protection through 2038.

We seek Safe Harbor.